Hi all, I'm back today talking about the approval of Avexis/Novartis' gene therapy for spinal muscular atrophy, Zolgensma. I also talk about how I came to a conclusion about whether or not I should short Biogen. Correction: The upcoming BIIB098 readout is not a pivotal study but a head-to-head against Tecfidera. Also, the partnership company is Alkermes, not Alkemes. Follow me on twitter @matthewlepoire www.breakingbiotech.com this is not investment advice Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech